Risk factors of cardiovascular adverse events in ChAdOx1-nCoV-19-vaccinated priority groups in North India

IF 1.7 Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Clinical Epidemiology and Global Health Pub Date : 2025-07-14 DOI:10.1016/j.cegh.2025.102124

Noti Taruni Srija Reddy , Mahek Rai , Sankha Shubhra Chakrabarti , Upinder Kaur

{"title":"Risk factors of cardiovascular adverse events in ChAdOx1-nCoV-19-vaccinated priority groups in North India","authors":"Noti Taruni Srija Reddy , Mahek Rai , Sankha Shubhra Chakrabarti , Upinder Kaur","doi":"10.1016/j.cegh.2025.102124","DOIUrl":null,"url":null,"abstract":"<div><h3>Rationale</h3><div>Studies on determinants of cardiovascular adverse events (CVAEs) in ChAdOx1-nCoV-19 vaccine recipients are scarce.</div></div><div><h3>Methods</h3><div>This is a subgroup analysis of our published one-year prospective study (February 2021 to April 2022) on the safety of the ChAdOx1-nCoV-19 vaccine. Healthcare workers and the elderly were the core study participants (priority vaccine recipients) who were followed up telephonically for one year after vaccination. Patterns of CVAEs and their risk factors were analyzed.</div></div><div><h3>Results</h3><div>Out of 1650 enrolled participants, the data on CVAEs were available for 1525. Cardiac AEs and vascular AEs occurred in 1.4 % and 1.8 %, respectively. CVAEs were serious in 0.45 % of participants. Obese individuals had 3.8- and 2-times higher odds of cardiac and vascular AEs, respectively. Individuals aged 40 years and above had 3 times higher odds of vascular AEs. Cardiac AEs were significantly more common after the first dose of the vaccine. No association was seen between CVAEs and COVID-19 before or after vaccination. The rates of persistent CVAEs were 2.4–3.1 %, 1.1–1.3 %, and 0.5–0.9 % in the Vaccine After COVID (VAC) group, COVID After Vaccine (CAV) group, and Vaccine NO COVID (VNC) group, respectively.</div></div><div><h3>Conclusion</h3><div>The occurrence of CVAEs might be governed by the number of vaccine doses, age, obesity, and timing of the vaccine with respect to natural SARS-CoV-2 infection. While no causality can be established between the observed events and vaccination, individuals receiving any dose of vaccine after recovery from COVID-19 need extended monitoring for CVAEs. Larger studies including unvaccinated individuals are required to understand the predictors of CVAEs for the individualization of future vaccination policies.</div></div>","PeriodicalId":46404,"journal":{"name":"Clinical Epidemiology and Global Health","volume":"35 ","pages":"Article 102124"},"PeriodicalIF":1.7000,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Epidemiology and Global Health","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213398425002131","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Rationale

Studies on determinants of cardiovascular adverse events (CVAEs) in ChAdOx1-nCoV-19 vaccine recipients are scarce.

Methods

This is a subgroup analysis of our published one-year prospective study (February 2021 to April 2022) on the safety of the ChAdOx1-nCoV-19 vaccine. Healthcare workers and the elderly were the core study participants (priority vaccine recipients) who were followed up telephonically for one year after vaccination. Patterns of CVAEs and their risk factors were analyzed.

Results

Out of 1650 enrolled participants, the data on CVAEs were available for 1525. Cardiac AEs and vascular AEs occurred in 1.4 % and 1.8 %, respectively. CVAEs were serious in 0.45 % of participants. Obese individuals had 3.8- and 2-times higher odds of cardiac and vascular AEs, respectively. Individuals aged 40 years and above had 3 times higher odds of vascular AEs. Cardiac AEs were significantly more common after the first dose of the vaccine. No association was seen between CVAEs and COVID-19 before or after vaccination. The rates of persistent CVAEs were 2.4–3.1 %, 1.1–1.3 %, and 0.5–0.9 % in the Vaccine After COVID (VAC) group, COVID After Vaccine (CAV) group, and Vaccine NO COVID (VNC) group, respectively.

Conclusion

The occurrence of CVAEs might be governed by the number of vaccine doses, age, obesity, and timing of the vaccine with respect to natural SARS-CoV-2 infection. While no causality can be established between the observed events and vaccination, individuals receiving any dose of vaccine after recovery from COVID-19 need extended monitoring for CVAEs. Larger studies including unvaccinated individuals are required to understand the predictors of CVAEs for the individualization of future vaccination policies.

查看原文本刊更多论文

印度北部chadox1 - ncov -19疫苗重点人群心血管不良事件的危险因素

关于ChAdOx1-nCoV-19疫苗接种者心血管不良事件（CVAEs）决定因素的研究很少。方法：这是我们发表的关于ChAdOx1-nCoV-19疫苗安全性的为期一年的前瞻性研究（2021年2月至2022年4月）的亚组分析。卫生保健工作者和老年人是研究的核心参与者（优先接种疫苗的人），他们在接种疫苗后进行了一年的电话随访。分析脑血管病的发病类型及危险因素。结果在1650名入组参与者中，1525名cvae数据可用。心脏ae和血管ae的发生率分别为1.4%和1.8%。0.45%的受试者cvae严重。肥胖个体发生心脏和血管不良反应的几率分别高出3.8倍和2倍。年龄在40岁及以上的人发生血管不良反应的几率要高出3倍。心脏不良反应在第一次接种疫苗后更为常见。在疫苗接种前后，CVAEs与COVID-19之间未见关联。COVID后疫苗（VAC）组、COVID后疫苗（CAV）组和无COVID疫苗（VNC）组持续cvae的发生率分别为2.4 ~ 3.1%、1.1 ~ 1.3%和0.5 ~ 0.9%。结论cvae的发生可能与自然感染SARS-CoV-2的疫苗剂量、年龄、肥胖和接种时间有关。虽然观察到的事件与疫苗接种之间没有因果关系，但从COVID-19恢复后接受任何剂量疫苗的个人需要延长对cvae的监测。需要进行更大规模的研究，包括未接种疫苗的个体，以了解cvae的预测因素，从而制定个性化的未来疫苗接种政策。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Epidemiology and Global Health PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-

CiteScore

4.60

自引率

7.70%

发文量

218

审稿时长

66 days

期刊介绍： Clinical Epidemiology and Global Health (CEGH) is a multidisciplinary journal and it is published four times (March, June, September, December) a year. The mandate of CEGH is to promote articles on clinical epidemiology with focus on developing countries in the context of global health. We also accept articles from other countries. It publishes original research work across all disciplines of medicine and allied sciences, related to clinical epidemiology and global health. The journal publishes Original articles, Review articles, Evidence Summaries, Letters to the Editor. All articles published in CEGH are peer-reviewed and published online for immediate access and citation.